TCGX logo

TCGX

Crunchbase
Pitchbook
Crunchbase

Deals on record

5

Common Fundraising Type

Series B

Aviceda Therapeutics is a biotech company developing next-generation immunomodulators for ophthalmic conditions using its proprietary HALOS™ nanotechnology platform.

Series C
$207.5M
01/07/2025
Article
Adcendo logo
Adcendo

Biotech

TCGX logo
Ysios Capital logo
Venrock Healthcare Capital Partners logo
Surveyor Capital logo
RA Capital Management logo
Pontifax Venture Capital logo
Novo Holdings logo
Logos Capital logo

Adcendo is a biotech company focused on developing antibody-drug conjugates for treating cancers with high unmet needs.

Series B
$135M
11/25/2024
Article
Vicebio logo
Vicebio

Biopharmaceutical

TCGX logo
venBio logo
UniQuest logo
Medicxi logo
Goldman Sachs Alternatives logo
Avoro Ventures logo

Vicebio Ltd is a biopharmaceutical company developing next-generation multivalent respiratory virus vaccines using proprietary Molecular Clamp technology.

Series B
$100M
09/23/2024
Article
Candid Therapeutics logo
Candid Therapeutics

Biotechnology

Venrock Healthcare Capital Partners logo
Vida Ventures logo
TCGX logo
Third Rock Ventures logo
Soleus Capital logo
Samsara BioCapital logo
Redmile Group logo
Polaris Innovation Fund logo

Candid Therapeutics, Inc. is a biotechnology company developing transformative therapies for autoimmune diseases.

Equity
$370M
09/09/2024
Article
Pathalys Pharma logo
Pathalys Pharma

Biopharmaceutical

TCGX logo
Samsara BioCapital logo
JP Morgan Life Sciences Private Capital logo
Marshall Wace logo
JPS Growth Investment Limited Partnership logo
KB Investment logo
DaVita Venture Group logo
Catalys Pacific logo

Pathalys Pharma is a biopharmaceutical company developing advanced therapeutics for end-stage kidney disease (ESKD).

Series B
$105M
08/20/2024
Article